

Remarks

Claims 1-44 are pending in the application. The Group I claims have been elected with traverse in part. The Group II Claims (Claims 2-8 and 22-23) have been cancelled as being directed to non-elected subject matter (i.e., compounds of formula I where A is C(R²)). Claim 9 was cancelled since it no longer provided a further limitation of Claim 1. Claims 1 and 21 have been amended to remove non-elected subject matter.


In accordance with the provisions of MPEP §821.04, Applicant respectfully request rejoinder of the Group III and Group V claims, if and when Claim 1 is found to be allowable.

Applicant respectfully submits that the Group IV claims are improperly restricted since all of the claims are dependent from Claim 26 which is part of the Group I claims. If Claim 26 is found to be allowable, then the Group IV claims would necessarily be novel and non-obvious since they contain further limitations upon Claim 26. Therefore, Group IV must be combined with Group I.

Respectfully Submitted:

Date:

February 16, 2006



Arlene K. Musser
Attorney for Applicants
Registration No. 37,895

Pfizer Inc.
Patent Department, MS: 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-0871